|
|
News Breaks | | | | December 3, 2012 | | 14:43 EDT |  | ABMD | Abiomed may have to obtain stringent approval for Impella, says Piper
Piper Jaffray predicts that Abiomed could be forced to obtain a PMA, or pre-market approval, for its Impella device. Pre-market approvals are the most stringent type of device marketing application required by the FDA, according to the agency's website. The firm thinks the company will have to conduct a series of new studies, but it maintains an Overweight rating on the stock, citing valuation. However, the firm expects the shares to remain range-bound in the near-term. | |
|
News For ABMD From The Last 14 Days Check below for free stories on ABMD the last two weeks. |
|
|
| May 13, 2013 | | 09:06 EDT | | ABMD | Abiomed price target raised to $28 from $22 at Stephens
 Subscribe for More Information | |
|
|
|
|
|
|
